VTCN1 - a cell membrane protein that inhibits T-cell responses and for which studies have shown that increased expression promotes cancer cell proliferation (Stelzer et al., 2016; Podojil and Miller, 2017), was, interestingly, upregulated in the cytoplasmic fractions in response to the drug treatments, raising thus interest for exploration in the context of immunotherapies. This evidence concerns the gene VTCN1 and cancer.